// App-Quantinova.ai

314 : Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).

Researchers

Presenter

  • Andrea Borghese Apolo

Principal Investigators

  • Young H. Lee

  • Fabiola Cecchi

  • Donald P. Bottaro

  • Piyush K. Agarwal

  • Howard L. Parnes

  • Kattie Khadar

  • Amelia Summerell

  • James L. Gulley

  • Kathryn Compton

  • William Douglas Figg

  • William L. Dahut

Medical Centers

  • Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.

  • National Cancer Institute, Bethesda, MD

  • Urologic Oncology Branch, National Cancer Institute, Bethesda, MD

  • Urologic Oncology Branch, National Cancer Institute, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Bladder Cancer

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Mitogen-activated protein kinase

  • Hepatocyte growth factor receptor

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved